225 related articles for article (PubMed ID: 37108918)
1. Clinical Uses of Inhaled Antifungals for Invasive Pulmonary Fungal Disease: Promises and Challenges.
Vuong NN; Hammond D; Kontoyiannis DP
J Fungi (Basel); 2023 Apr; 9(4):. PubMed ID: 37108918
[TBL] [Abstract][Full Text] [Related]
2. Inhaled amphotericin B for prophylaxis against invasive Aspergillus infections.
Mohammad RA; Klein KC
Ann Pharmacother; 2006 Dec; 40(12):2148-54. PubMed ID: 17148653
[TBL] [Abstract][Full Text] [Related]
3. Tolerability and outcome of once weekly liposomal amphotericin B for the prevention of invasive fungal infections in hematopoietic stem cell transplant patients with graft-versus-host disease.
Luu Tran H; Mahmoudjafari Z; Rockey M; Henry D; Grauer D; Aljitawi O; Abhyankar S; Ganguly S; Lin T; McGuirk J
J Oncol Pharm Pract; 2016 Apr; 22(2):228-34. PubMed ID: 25471252
[TBL] [Abstract][Full Text] [Related]
4. Inhaled Amphotericin B as Aspergillosis Prophylaxis in Hematologic Disease: An Update.
Duckwall MJ; Gales MA; Gales BJ
Microbiol Insights; 2019; 12():1178636119869937. PubMed ID: 31496719
[TBL] [Abstract][Full Text] [Related]
5. Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections.
Moen MD; Lyseng-Williamson KA; Scott LJ
Drugs; 2009; 69(3):361-92. PubMed ID: 19275278
[TBL] [Abstract][Full Text] [Related]
6. Antifungal prophylaxis in adult lung transplant recipients: Uncertainty despite 30 years of experience. A systematic review of the literature and network meta-analysis.
Marinelli T; Davoudi S; Foroutan F; Orchanian-Cheff A; Husain S
Transpl Infect Dis; 2022 Jun; 24(3):e13832. PubMed ID: 35388588
[TBL] [Abstract][Full Text] [Related]
7. A targeted peritransplant antifungal strategy for the prevention of invasive fungal disease after lung transplantation: a sequential cohort analysis.
Koo S; Kubiak DW; Issa NC; Dietzek A; Boukedes S; Camp PC; Goldberg HJ; Baden LR; Fuhlbrigge AL; Marty FM
Transplantation; 2012 Aug; 94(3):281-6. PubMed ID: 22790447
[TBL] [Abstract][Full Text] [Related]
8. Safety of Inhaled Amphotericin B Lipid Complex as Antifungal Prophylaxis in Lung Transplant Recipients.
Huggins JP; Pease R; Stanly K; Workman A; Reynolds J; Alexander BD
Antimicrob Agents Chemother; 2022 Jun; 66(6):e0028322. PubMed ID: 35506698
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of targeted versus universal prophylaxis for the prevention of invasive fungal infections following lung transplantation.
Linder KA; Kauffman CA; Patel TS; Fitzgerald LJ; Richards BJ; Miceli MH
Transpl Infect Dis; 2021 Feb; 23(1):e13448. PubMed ID: 33448560
[TBL] [Abstract][Full Text] [Related]
10. EPICO 3.0. Empirical antifungal therapy in critically-ill hematology patients.
Llinares P; Ruiz I; Zaragoza R; Ferrer R; Rodríguez AH; Maseda E; Grau S;
Rev Iberoam Micol; 2016; 33(4):206-215. PubMed ID: 27751781
[TBL] [Abstract][Full Text] [Related]
11. Mold infections in lung transplant recipients.
Bhaskaran A; Hosseini-Moghaddam SM; Rotstein C; Husain S
Semin Respir Crit Care Med; 2013 Jun; 34(3):371-9. PubMed ID: 23821511
[TBL] [Abstract][Full Text] [Related]
12. Antifungal Prophylaxis in Lung Transplant Recipients.
Patel TS; Eschenauer GA; Stuckey LJ; Carver PL
Transplantation; 2016 Sep; 100(9):1815-26. PubMed ID: 26950711
[TBL] [Abstract][Full Text] [Related]
13. Invasive fungal infections in lung transplantation: role of aerosolised amphotericin B.
Solé A
Int J Antimicrob Agents; 2008 Nov; 32 Suppl 2():S161-5. PubMed ID: 19013342
[TBL] [Abstract][Full Text] [Related]
14. Itraconazole oral solution for primary prophylaxis of fungal infections in patients with hematological malignancy and profound neutropenia: a randomized, double-blind, double-placebo, multicenter trial comparing itraconazole and amphotericin B.
Harousseau JL; Dekker AW; Stamatoullas-Bastard A; Fassas A; Linkesch W; Gouveia J; De Bock R; Rovira M; Seifert WF; Joosen H; Peeters M; De Beule K
Antimicrob Agents Chemother; 2000 Jul; 44(7):1887-93. PubMed ID: 10858349
[TBL] [Abstract][Full Text] [Related]
15. Is universal antifungal prophylaxis mandatory in lung transplant patients?
Schaenman JM
Curr Opin Infect Dis; 2013 Aug; 26(4):317-25. PubMed ID: 23743815
[TBL] [Abstract][Full Text] [Related]
16. Long-term antifungal prophylaxis in high-risk hematopoietic stem cell transplant recipients.
Bow EJ
Med Mycol; 2005 May; 43 Suppl 1():S277-87. PubMed ID: 16110821
[TBL] [Abstract][Full Text] [Related]
17. Voriconazole versus amphotericin B or fluconazole in cancer patients with neutropenia.
Jørgensen KJ; Gøtzsche PC; Dalbøge CS; Johansen HK
Cochrane Database Syst Rev; 2014 Feb; 2014(2):CD004707. PubMed ID: 24563222
[TBL] [Abstract][Full Text] [Related]
18. Inhaled Antifungal Agents for Treatment and Prophylaxis of Bronchopulmonary Invasive Mold Infections.
Brunet K; Martellosio JP; Tewes F; Marchand S; Rammaert B
Pharmaceutics; 2022 Mar; 14(3):. PubMed ID: 35336015
[TBL] [Abstract][Full Text] [Related]
19. Management of Invasive Fungal Infections in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: The Turin Experience.
Busca A; Cinatti N; Gill J; Passera R; Dellacasa CM; Giaccone L; Dogliotti I; Manetta S; Corcione S; De Rosa FG
Front Cell Infect Microbiol; 2021; 11():805514. PubMed ID: 35071052
[TBL] [Abstract][Full Text] [Related]
20. Prophylaxis with nebulized liposomal amphotericin B for Aspergillus infection in lung transplant patients does not cause changes in the lipid content of pulmonary surfactant.
Monforte V; López-Sánchez A; Zurbano F; Ussetti P; Solé A; Casals C; Cifrian J; de Pablos A; Bravo C; Román A
J Heart Lung Transplant; 2013 Mar; 32(3):313-9. PubMed ID: 23332731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
